Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

• Status: RECRUITING
• Trial end date: 2026-01-31

Summary

This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.

• Phase: PHASE4

Details

• Lead Sponsor: Evi Liliek Wulandari
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Ramipril